The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Walmart's valuation may be overhyped amidst industry headwinds and risks like SNAP cuts, tariffs, and shifting consumer ...

Weight loss medications can reduce the efficacy of oral contraceptives. What to know before taking drugs like Ozempic, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Several top nutrition and obesity organizations provided the first unified guidelines for helping patients manage their ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...